{"id":5179,"date":"2022-03-25T13:09:32","date_gmt":"2022-03-25T13:09:32","guid":{"rendered":"https:\/\/www.nfp-drugs.bg\/en\/?p=5179"},"modified":"2022-03-31T11:26:49","modified_gmt":"2022-03-31T11:26:49","slug":"risk-assessments-emcdda","status":"publish","type":"post","link":"https:\/\/www.nfp-drugs.bg\/en\/risk-assessments-emcdda\/","title":{"rendered":"Risk assessments (EMCDDA)"},"content":{"rendered":"\n

(35) Report on the risk assessment of 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) in accordance with Article 5c of Regulation (EC) No 1920\/2006 (2022)<\/a><\/p>\n\n\n\n

(34) Report on the risk assessment of 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC) in accordance with Article 5c of Regulation (EC) No 1920\/2006 (2022)<\/a><\/p>\n\n\n\n

(33) Report on the risk assessment of methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dime- thylbutanoate (4F-MDMB-BICA) in accordance with Article 5c of Regulation (EC) No 1920\/2006 (2021)<\/a><\/p>\n\n\n\n

(32) Report on the risk assessment of methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-car- bonyl]amino}butanoate (MDMB-4en-PINACA) in accordance with Article 5c of Regulation (EC) No 1920\/2006 (2021)<\/a><\/p>\n\n\n\n

(31) Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920\/2006 (2020)<\/a>

(30) Report on the risk assessment of 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) in the framework of the Council Decision on new psychoactive substances (2018)<\/a><\/p>\n\n\n\n

(29) Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) in the framework of the Council Decision on new psychoactive substances (2018)<\/a><\/p>\n\n\n\n

(28) Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances (2018)<\/a><\/p>\n\n\n\n

(27) Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4- yl]oxolane-2-carboxamide (THF-F) in the framework of the Council Decision on new psychoactive substances (2018)<\/a><\/p>\n\n\n\n

(26) Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF) in the framework of the Council Decision on new psychoactive substances (2018)<\/a><\/p>\n\n\n\n

(25) Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA) in the framework of the Council Decision on new psychoactive substances (2018)<\/a><\/p>\n\n\n\n

(24) Report on the risk assessment of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) in the framework of the Council Decision on new psychoactive substances (2018)<\/a><\/p>\n\n\n\n

(23) Report on the risk assessment of 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in the framework of the Council Decision on new psychoactive substances (2018)<\/a><\/p>\n\n\n\n

(22) Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) in the framework of the Council Decision on new psychoactive substances (2018)<\/a><\/p>\n\n\n\n

(21) Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) in the framework of the Council Decision on new psychoactive substances (2017)<\/a><\/p>\n\n\n\n

(20) Report on the risk assessment of N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) in the framework of the Council Decision on new psychoactive substances (2017)<\/a><\/p>\n\n\n\n

(19) Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA) in the framework of the Council Decision on new psychoactive substances (2017)<\/a><\/p>\n\n\n\n

(18) Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (\u03b1-pyrrolidinovalerophenone, \u03b1-PVP) (2016)<\/a><\/p>\n\n\n\n

(17) Report on the risk assessment of MT-45 in the framework of the Council Decision on new psychoactive substances (2015)<\/a><\/p>\n\n\n\n

(16) Report on the risk assessment of 4,4\u2032-DMAR in the framework of the Council Decision on new psychoactive substances (2015)<\/a><\/p>\n\n\n\n

(15) Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) in the framework of the Council Decision on new psychoactive substances (2014)<\/a><\/p>\n\n\n\n

(14) Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV) in the framework of the Council Decision on new psychoactive substances (2014)<\/a><\/p>\n\n\n\n

(13) Report on the risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (AH-7921) in the framework of the Council Decision on new psychoactive substances (2014)<\/a><\/p>\n\n\n\n

(12) Report on the risk assessment of 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) in the framework of the Council Decision on new psychoactive substances (2014)<\/a><\/p>\n\n\n\n

(11) Report on the risk assessment of 5-(2-aminopropyl)indole (5-IT) in the framework of the Council Decision on new psychoactive substances (2014)<\/a><\/p>\n\n\n\n

(10) Report on the risk assessment of 4-methylamphetamine (4-MA) in the framework of the Council Decision on new psychoactive substances (2014)<\/a><\/p>\n\n\n\n

(9) Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances (2011)<\/a><\/p>\n\n\n\n

(8) Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances (2009)<\/a><\/p>\n\n\n\n

(7) Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs (2004)<\/a><\/p>\n\n\n\n

(6) Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs (2004)<\/a><\/p>\n\n\n\n

(5) Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs (2003)<\/a><\/p>\n\n\n\n

(4) Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs (2002)<\/a><\/p>\n\n\n\n

(3) Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs (2002)<\/a><\/p>\n\n\n\n

(2) Report on the risk assessment of 4-MTA in the framework of the joint action on new synthetic drugs (1999)<\/a><\/p>\n\n\n\n

(1) Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs (1999)<\/a><\/p>\n\n\n\n

Early-warning system on new psychoactive substances \u2014 operating guidelines<\/a><\/p>\n\n\n\n

Risk assessment of new psychoactive substances \u2014 operating guidelines<\/a><\/p>\n\n\n\n

Guidelines for the risk assessment of new synthetic drugs<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

(35) Report on the risk assessment of 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) in accordance with Article 5c of Regulation (EC) No 1920\/2006 (2022) (34) Report on the risk assessment of 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC) in accordance with Article 5c of Regulation (EC) No 1920\/2006 (2022) (33) Report on the risk assessment of methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dime- thylbutanoate (4F-MDMB-BICA) in accordance […]<\/p>\n","protected":false},"author":1,"featured_media":5180,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,11],"tags":[59,58,61],"_links":{"self":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/5179"}],"collection":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/comments?post=5179"}],"version-history":[{"count":6,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/5179\/revisions"}],"predecessor-version":[{"id":5201,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/5179\/revisions\/5201"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media\/5180"}],"wp:attachment":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media?parent=5179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/categories?post=5179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/tags?post=5179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}